Adaptive Biotechnologies
1551 Eastlake Ave E
Suite 200
Seattle
Washington
98102
United States
129 articles with Adaptive Biotechnologies
-
Adaptive Biotech Enters Drug Discovery With Launch of New Company, Adaptive Therapeutics
8/20/2015
-
23andMe Taps Former Adaptive Biotech Exec as CFO and Head of Ops
8/17/2015
-
Will New CFO Take Adaptive Biotech Public?
8/11/2015
-
Adaptive Biotech Welcomes Chad Cohen As Its New Chief Financial Officer
8/10/2015
-
Adaptive Biotech And Collaborators Demonstrate Importance Of Minimal Residual Disease Measurement In Response Evaluation For Multiple Myeloma
7/15/2015
-
Seattleās Adaptive Biotech Will Set Up Shop in New York
7/2/2015
-
Adaptive Biotech To Present Data From Largest Study To Date Demonstrating Superior Sensitivity And Prognostic Value Of Next-Generation Sequencing-Based Minimal Residual Disease (MRD) Detection In Pediatric Acute Lymphoblastic Leukemia
6/12/2015
-
Children's Oncology Group/Pediatric Blood And Marrow Transplant Consortium Study Shows Adaptive Biotech' clonoSEQ Minimal Residual Disease (MRD) Test Superior To Flow Cytometry In Predicting Post-Transplant Relapse And Survival In Acute Lymphoblastic Leuk
6/4/2015
-
Here's What Juno Therapeutics Really Thinks About Local Rival Adaptive Biotech
6/1/2015
-
ASCO15: Adaptive Biotech And Collaborators To Present Eight Studies At The 2015 American Society Of Clinical Oncology Annual Meeting Demonstrating The Relevance Of Monitoring Immune Receptors As A New Class Of Biomarkers
5/29/2015
-
Four Seattle Biotech Firms Looking to Hire Hundreds of New Employees
5/26/2015
-
Adaptive Biotech' immunoSEQ Assay Provides Groundbreaking Insight Into T-Cell Fate, Significantly Advancing Understanding Of Adaptive Immunity
5/12/2015
-
Adaptive Biotech And Collaborators To Present 5 Studies Demonstrating Utility Of Immunosequencing To Determine T-Cell Function In Chronic And Infectious Diseases At The 2015 American Association Of Immunologists Annual Meeting
5/8/2015
-
Adaptive Biotech Bags $195 Million In Largest Washington Fundraise This Year
5/7/2015
-
Adaptive Biotechnologies And Researchers From MD Anderson Cancer Center Demonstrate Ability To Detect Hodgkin's Lymphoma In Blood
4/28/2015
-
Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Detects Relapse With Higher Specificity Than PET/CT In Diffuse Large B-Cell Lymphoma Patients
4/22/2015
-
Adaptive Biotechnologies And Collaborators To Present 4 Studies Demonstrating Clinical Relevance Of Immunosequencing In The Treatment Of Solid Tumors At The 2015 American Association for Cancer Research Annual Meeting
4/15/2015
-
Multiple Myeloma Research Foundation (MMRF), University Of Torino, And Adaptive Biotechnologies Work To Speed Novel Minimal Residual Disease Monitoring Technologies To Patients
4/14/2015
-
Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse In Diffuse Large B-Cell Lymphoma Patients By Sensitively Detecting Circulating Tumor DNA
4/2/2015
-
Adaptive Biotechnologies Invited To Present At Upcoming Conferences
3/17/2015